Impact of Anxiety Levels and Sleep Patterns on Perceived Pain During Intravitreal Bevacizumab Injections

Ophthalmic Surg Lasers Imaging Retina. 2021 Sep;52(9):498-504. doi: 10.3928/23258160-20210819-02. Epub 2021 Sep 1.

Abstract

Background and objective: To evaluate the impact of anxiety and sleep patterns on intravitreal injection pain.

Patients and methods: This prospective, noninterventional study surveyed patients scheduled for intravitreal injection by two retinal surgeons. A standard intravitreal injection technique was used. Patients filled out pre-procedure General Anxiety Disorder-7 (GAD-7) and Pittsburgh Sleep Quality Index (PSQI) questionnaires. Post-procedural pain was assessed with a visual analogue scale. Quality and hours of sleep and anxiety levels were correlated with perceived intravitreal injection pain.

Results: A total of 140 patients met inclusion criteria. Mean ± standard deviation scores were 4.9 ± 5.6 for the GAD-7, 6.3 ± 4.1 for the PSQI, and 3.69 ± 2.64 for intravitreal injection pain. Anxiety correlated with intravitreal injection pain (rho = 0.25; P = .003). Previous night's sleep (rho = -0.16; P = .057) and poor sleep quality (rho = 0.14; P = .11) were weakly correlated. Regression analysis revealed anxiety was the only significant predictor of intravitreal injection pain. A 1-point increase in anxiety predicted a 0.10-point increase in intravitreal injection pain (B = 0.10, P = .032).

Conclusions: Anxiety level was the best predictor of perceived pain. This has implications for pre-procedural anxiety screening. [Ophthalmic Surgery Lasers Imaging Retina. 2021;52:498-504.].

MeSH terms

  • Angiogenesis Inhibitors* / therapeutic use
  • Anxiety / etiology
  • Bevacizumab
  • Humans
  • Intravitreal Injections
  • Pain Perception
  • Pain* / drug therapy
  • Pain* / etiology
  • Prospective Studies
  • Sleep

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab